NeuroOne Medical Technologies Corp. Files 8-K

TL;DR

NeuroOne Medical Technologies filed an 8-K on Oct 6, 2025, updating on operations and financials.

AI Summary

NeuroOne Medical Technologies Corp. filed an 8-K on October 6, 2025, reporting on its results of operations, financial condition, and other events. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Eden Prairie, MN.

Why It Matters

This 8-K filing provides an update on NeuroOne Medical Technologies Corp.'s operational and financial status, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not contain specific material events that would inherently increase risk.

Key Players & Entities

• NeuroOne Medical Technologies Corp. (company) — Registrant
• October 6, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Eden Prairie, MN (location) — Principal Executive Offices
• 952 - 426-1383 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share NMTC The Nasdaq Stock Mar
• $9.1 million — total product revenue of approximately $9.1 million. Cash and cash equivalents of approxi
• $6.6 million — h and cash equivalents of approximately $6.6 million at September 30, 2025. Item 9.01 Fina

Filing Documents

• ea0260404-8k_neuroone.htm (8-K) — 29KB
• ea026040401ex99-1_neuroone.htm (EX-99.1) — 13KB
• ex99-1_001.jpg (GRAPHIC) — 7KB
• 0001213900-25-096548.txt ( ) — 219KB
• nmtc-20251006.xsd (EX-101.SCH) — 3KB
• nmtc-20251006_lab.xml (EX-101.LAB) — 33KB
• nmtc-20251006_pre.xml (EX-101.PRE) — 22KB
• ea0260404-8k_neuroone_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On October 6, 2025, NeuroOne Medical Technologies Corporation (the "Company") issued a press release announcing certain preliminary, unaudited financial results for the fiscal year ended September 30, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibit 99.1 attached hereto, shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly stated by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events Preliminary Results On October 6, 2024, the Company reported the following preliminary unaudited fiscal year 2025 financial and operational results: Achieved annual total product revenue of approximately $9.1 million. Cash and cash equivalents of approximately $6.6 million at September 30, 2025.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 6, 2025 104 Cover Page Interactive Data File (embedded with Inline XBRL document).

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company's revenue results, financial outlook, product demand, commitments or opportunities, and growth expectations or targets, as well as statements that include the words "expect," "intend," "plan", "believe", "project", "forecast", "estimate," "may," "should," "anticipate" and similar statements of a future or forward looking nature. These forward-looking year contained in this Current Report on Form 8-K are subject to the completion of management's and the audit committee's final reviews and our other financial closing procedures and are therefore subject to change. You should not place undue reliance on such preliminary information and estimates because they may prove to be materially inaccurate. The preliminary information and estimates have not been compiled or examined by our independent auditors and they are subject to revision as we prepare our financial statements as of and for the fiscal year ended September 30, 2025, including all disclosures required by U.S. generally accepted accounting principles. While we believe that such preliminary information and estimates are based on reasonable assumptions, actual results may vary, and such variations may be material. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may no

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROONE MEDICAL TECHNOLOGIES CORPORATION Dated: October 6, 2025 By: /s/ David Rosa David Rosa Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR